SAN DIEGO--(BUSINESS WIRE)--Adamis Pharmaceuticals Corporation (OTCBB: ADMP), a commercial-stage specialty pharmaceutical company, announced that its subsidiary, Adamis Viral Therapies, has demonstrated in a preclinical trial that its patented vaccine technology induces cross-protective immunity against the influenza virus by attacking regions of the virus that are not subject to mutation.
